Huntington National Bank’s Vaxcyte PCVX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$21.4K Hold
369
– – ﹤0.01% 1738
2026
Q1
$21.4K Hold
369
– – ﹤0.01% 1624
2025
Q4
$17K Hold
369
– – ﹤0.01% 1632
2025
Q3
$13.3K Buy
369
+217
+143% +$7.19K ﹤0.01% 1740
2025
Q2
$4.94K Sell
152
-16
-10% -$525 ﹤0.01% 2008
2025
Q1
$6.34K Buy
168
+16
+11% +$1.28K ﹤0.01% 1907
2024
Q4
$12.4K Buy
152
+5
+3% +$496 ﹤0.01% 1697
2024
Q3
$16.8K Buy
147
+124
+539% +$11.2K ﹤0.01% 1568
2024
Q2
$1.74K Buy
23
+18
+360% +$1.23K ﹤0.01% 2192
2024
Q1
$342 Buy
+5
New +$346 ﹤0.01% 2386
2023
Q4
– Sell
-18
Closed -$918 – 3934
2023
Q3
$918 Buy
+18
New +$888 ﹤0.01% 2222

Other funds holding PCVX

Huntington National Bank's PCVX Position: Q2 2026 in Review

Huntington National Bank held its Vaxcyte (PCVX) position steady in Q2 2026 at 369 shares worth $21.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1738.

Huntington National Bank first reported a position in PCVX in Q3 2023 and has held it in 11 quarters since. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Huntington National Bank held 369 shares of Vaxcyte worth $21.4K as of Q2 2026.
  • Huntington National Bank left its Vaxcyte share count unchanged in Q2 2026.
  • Vaxcyte made up ﹤0.01% of Huntington National Bank's portfolio in Q2 2026, its #1738 holding.
  • Huntington National Bank first reported a position in Vaxcyte in Q3 2023 and has held it in 11 quarters since.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Huntington National Bank's 13F filing for Q2 2026, filed 13 Aug 2026.